SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — History and Physical — George H. W. Bush — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | George H. W. Bush |
|---|
| Date of birth | 1924-06-12 |
|---|
| Identifiers | MRN HR-ML018-SYN-TD; SSN (made up) 000-18-7245 |
|---|
| Document date | 1991-05-08 |
|---|
| Author | Douglas Whitford, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Visit
Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism [S]
History of Present Illness
This fictional modern episode addresses the presenting concerns below. [S]
- New irregular heartbeat that began as unusual tiredness on a run; wants to know whether he can keep running. [S]
- Wants to get back to a full working schedule and to exercise as soon as it is safe. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- George Herbert Walker Bush was born in Milton, Massachusetts, on June 12, 1924. [D]
- On May 4, 1991, he developed atrial fibrillation while running at Camp David; it presented as unusual fatigue during the run. He was flown to Bethesda Naval Hospital, where an electrocardiogram showed no abnormality except the irregular rhythm and a cardiac ultrasound showed no structural abnormality and normal heart function. Treatment began with digoxin. [D]
- On May 5, 1991, the White House said he still had atrial fibrillation, with no sign of heart damage or heart attack, and that procainamide had been added to digoxin; electrical cardioversion would be considered if the rhythm did not return to normal. [D]
- His normal rhythm returned late on May 5, atrial fibrillation recurred early on May 6, and cardioversion was judged unnecessary because his response to medication was encouraging. He was discharged on May 6 and was in normal sinus rhythm later that day, on digoxin and procainamide. [D]
- Later in the same week he was diagnosed with Graves' disease. [D]
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| May 4, 1991 | Atrial fibrillation that began as unusual fatigue while running; hospital stay of two days, with normal ECG apart from the rhythm and a normal cardiac ultrasound; sinus rhythm restored on medication without cardioversion | D (CLM-0002, CLM-0003, CLM-0004) |
Family History
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
Social History
- Never used tobacco; alcohol rarely, a glass of wine with dinner; no other drug use [S]
- Works full time in a demanding executive role with frequent travel; married and lives with his spouse [S]
- Runs about three miles four or five days a week; stopped running after the hospital stay on advice to build back gradually [S]
- Two to three cups of coffee a day; no energy drinks or decongestants [S]
- Supports: spouse, adult children, and close colleagues and friends [S]
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet each morning | Oral route | 1991-05-05 to 1991-07-17 | stopped | S |
| Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) | One tablet twice daily | Oral route | 1991-05-05 to 1991-09-11 | stopped | S |
| Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily | Two tablets once daily; stop three days before radioactive iodine | Oral route | 1991-05-08 to 1991-05-26 | completed | S |
Review of Systems
Positive for the concerns in the history of present illness. Alert, cheerful, and talkative. Mood good. No other systems reported as affected in this synthetic episode. [S]
General Status
Alert and engaged. At intake, independent in all activities but more tired than usual on runs, with some weight loss despite a good appetite. Back to running three miles four days a week without palpitations by the four-month review. [S]
Physical Exam
Vital signs recorded on 1991-05-08; see the Vital Signs section. Mental status: Alert, cheerful, and talkative; Mood good. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 1991-05-08 | Body height | 188 | cm | S |
| 1991-05-08 | Body weight | 86 | kg | S |
| 1991-05-08 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 1991-05-08 | Systolic blood pressure | 142 | mm[Hg] | S |
| 1991-05-08 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1991-05-08 | Heart rate | 88 | /min | S |
| 1991-05-08 | Respiratory rate | 16 | /min | S |
| 1991-05-08 | Body temperature | 37.1 | Cel | S |
| 1991-05-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1991-05-08 | Thyrotropin [Units/volume] in Serum or Plasma | 0.005 | m[IU]/L | 0.4-4 mIU/L | Low | S |
| 1991-05-08 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 3.6 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 1991-05-08 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 280 | ng/dL | 80-200 ng/dL | High | S |
| 1991-05-08 | Thyrotropin receptor Ab [Units/volume] in Serum | 8.2 | [IU]/L | <=1.75 [IU]/L | High | S |
| 1991-05-08 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1991-05-08 | Neutrophils [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 1.5-7.5 10*3/uL | Normal | S |
| 1991-05-08 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1991-05-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 7-55 U/L | Normal | S |
| 1991-05-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1991-05-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1986)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1991-05-08 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation | active | confirmed |
I48.0 | S — Synthetic modern classification of a documented arrhythmia. |
| Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease | active | confirmed |
E05.00 | S — Synthetic modern diagnosis confirmed by thyroid tests and TSH receptor antibody; the historical diagnosis is D. |
Assessment
- Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation: active, confirmed [S]
- Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease: active, confirmed [S]
Plan of Treatment
- Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) [S]
- Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) [S]
- Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) [S]
- Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery). Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) [S]
- Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) [S]
- Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) [S]
- Referral to endocrinology, Anjali Kapoor, MD, ordered 1991-05-08 [S]